Supplier
Glen Cove Hospital
Glen Cove Hospital was paid $7.72M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoGLEN COVE HOSPITAL
GLEN COVE, NY 11542
GLEN COVE, NY 11542
33aNPI1295743060assigned 08/04/2006
33bProvider typeCommunity/Retail Pharmacy
28Total paid$7.72M
24GClaims140,884
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Community/Retail Pharmacy providers in New York
Rank by total paid#4 of 129
Median peer was paid$2K
This provider vs. median3,789×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUSACK, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 228 | $11K | |
| 2019 | 4,843 | $305K | |
| 2020 | 15,628 | $1.00M | |
| 2021 | 27,903 | $1.69M | |
| 2022 | 32,592 | $1.68M | |
| 2023 | 34,025 | $1.73M | |
| 2024incomplete | 25,665 | $1.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 7,604 | 7,099 | $1.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 5,627 | 5,248 | $976K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.5% | 6,285 | 5,062 | $733K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.2% | 7,225 | 1,813 | $559K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 2,708 | 2,511 | $488K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.3% | 1,656 | 1,586 | $332K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 1,669 | 1,637 | $322K |
| 36415 | Collection of venous blood by venipuncture | 3.7% | 18,069 | 8,964 | $287K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 3.4% | 5,198 | 1,323 | $261K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 1,151 | 1,128 | $260K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.7% | 1,577 | 1,560 | $211K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.6% | 1,753 | 1,728 | $198K |
106 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 1,053 | $198K |
| 80053 | Comprehensive metabolic panel | 1.8% | 7,582 | $135K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.7% | 1,540 | $130K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 804 | $118K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 1,802 | $117K |
| 76641 | 1.5% | 1,317 | $117K | |
| 76830 | Ultrasound, transvaginal | <1% | 666 | $71K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 287 | $49K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,751 | $46K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 341 | $39K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 146 | $38K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,346 | $33K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 180 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,563 | $32K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 756 | $26K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,069 | $23K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,279 | $23K |
| J3490 | Unclassified drugs | <1% | 2,178 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,804 | $22K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,524 | $20K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 323 | $18K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 75 | $18K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 179 | $17K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 172 | $16K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 52 | $16K |
| 0225U | <1% | 1,358 | $15K | |
| 97161 | <1% | 131 | $15K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,816 | $14K |
| 86850 | <1% | 480 | $13K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 900 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,627 | $11K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $10K |
| 86900 | <1% | 486 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,085 | $9K |
| 71250 | <1% | 71 | $9K | |
| 80061 | Lipid panel | <1% | 848 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 661 | $8K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 63 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,136 | $7K |
| 86901 | <1% | 454 | $7K | |
| 76536 | <1% | 78 | $7K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 857 | $6K |
| 77080 | <1% | 77 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,697 | $4K |
| C9399 | Unclassified drugs or biologicals | <1% | 100 | $4K |
| 73562 | <1% | 196 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 401 | $3K |
| 87631 | <1% | 65 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 480 | $3K |
| 73610 | <1% | 157 | $3K | |
| 85027 | <1% | 2,151 | $3K | |
| 73630 | <1% | 121 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,084 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,625 | $2K |
| 85610 | <1% | 767 | $2K | |
| 83880 | <1% | 90 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,786 | $2K |
| 86769 | <1% | 53 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 598 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 49 | $1K |
| 73130 | <1% | 25 | $1K | |
| 81025 | <1% | 586 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 626 | $1K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 40 | $1K |
| 72100 | <1% | 38 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 595 | $1K |
| 73110 | <1% | 38 | $1K | |
| 73030 | <1% | 52 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,232 | $976.15 |
| 84702 | <1% | 826 | $946.53 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 439 | $928.73 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 627 | $911.16 |
| 81001 | <1% | 1,950 | $894.91 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 792 | $864.02 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 590 | $859.37 |
| J7170 | Injection, emicizumab-kxwh, 0.5 mg | <1% | 13 | $800.24 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 19 | $789.24 |
| 88307 | <1% | 12 | $782.47 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 267 | $775.14 |
| G0008 | Administration of influenza virus vaccine | <1% | 128 | $736.80 |
| 36000 | <1% | 30 | $624.92 | |
| 84484 | <1% | 1,445 | $611.80 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 307 | $590.03 |
| 83690 | <1% | 2,032 | $559.85 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 623 | $542.16 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 20 | $478.81 |
| 72040 | <1% | 15 | $473.98 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 587 | $451.49 |
| 85730 | <1% | 507 | $332.08 | |
| 82962 | <1% | 610 | $268.45 | |
| 87581 | <1% | 20 | $249.02 | |
| 87486 | <1% | 20 | $249.02 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 77 | $192.90 |
| 83735 | <1% | 370 | $171.56 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $129.43 |
| 86803 | <1% | 15 | $110.30 | |
| 81002 | <1% | 141 | $96.28 | |
| 85379 | <1% | 69 | $60.72 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 33 | $53.10 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $30.72 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 18 | $27.02 |
| 81003 | <1% | 46 | $23.30 | |
| 88312 | <1% | 49 | $13.18 | |
| 87081 | 0% | 14 | $0.00 | |
| 87040 | 0% | 15 | $0.00 | |
| 83605 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUSACK, MICHELE (SENIOR VP & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.